BioData EU 2018 - Agenda Day 2

 

BioData EU- Day 2

08:55

Chair’s opening remarks

Stefan Platz
09:00

Transforming R&D productivity: How can we better turn science into medicine?

  • The future treatment for many of today’s diseases lies in discovering new biology to develop novel therapies. The advent of the genomics revolution brings with it an expanding list of pathways and targets to pursue – and with it, new drug discovery challenges
  • Validating drug targets by understanding and challenging scientific hypotheses has never been more important
  • Combining new technologies, focusing on medical understanding, challenging scientific hypotheses and driving strategic partnerships, we are making real progress in our ability to define and prosecute innovative treatment approaches for a variety of complex diseases
Ravinder Singh
09:20

Data Driven digital architecture : Getting ready for new normal for life sciences

Digital transformation is ready to scale into mainstream business challenging the boundaries of existing enterprise architectures. The next generation pharma Enterprise architecture blueprint will be built over the principles of Agile and democratized data, new technology incubations with right sized controls. Key elements of this next gen architecture blueprint addresses transformative themes of closed loop patient relationship, multi-disciplinary data management and extensive partner collaboration to build a sustainable digital ready enterprise architecture for next generation Life Sciences organizations.
10:00

Day One Initiative

Morning Refreshments

AI, AUTOMATION AND MACHINE LEARNING

ANALYTICS PLATFORMS AND DATA SETS

NEXT GEN SEQUENCING

DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS

ROCHE CURATED SESSION

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:00

Chairs Opening Remarks

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
11:00

Chairs Opening Remarks

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
11:00

Chairs Opening Remarks

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:00

Chairs Opening Remarks

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:05

Using analytics tools to leverage data

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:05

ROCHE CURATED SESSION

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:25

Realizing at scale genotypic-phenotypic analytics

  • Utilising the largest clinico-genomic database
  • Analytics platforms and the IQVIA & GeL partnership
  • Reinforcing the partnership via opportunities beyond the UK
Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
11:25

GENALICE

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
11:25

Adaptive Power Enhanced Multiple Testing

  • Classical multiple testing for example, when analyzing genomic data, relies on adjusting p-values to control the family wise error rate (FWER) or the false discovery rate (FDR). However, the power of the individual hypothesis are not taken into account which results in sub-optimal alpha allocation.
  • We propose an adaptive method that uses a small proportion data to inform on the individual power of each hypothesis (gene).
  • Following this, an adaptive alpha-allocation is carried out that minimizes the missed discovery rate (MDR) while controlling the FWER or FDR at a pre-specified level. An example from a microarray experiment will be used to illustrate and compare the procedure with classical methods.
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:25

Sponsor Available

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
11:45

Machine Learning meets the Human Genome

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
11:45

A comprehensive analysis of a RNA-seq dataset at the gene-, isoform- and exon-levels to discover disease progressive biomarkers during diabetic nephropathy

  • Introduction to ZSF1, a preclinical model for type 2 diabetic nephropathy
  • Why RNA-seq data should be additionally analyzed at the isoform and exon levels
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
11:45

Use case: Federated EHR research technology to support clinical trial protocol optimisation: Evidence from EHR4CR and the InSite platform

  • The new federated EHR technology approach – the case of EHR4CR project and deployment program inEurope
  • Utilise a combination of data sources to effectively structure your developmental strategy
  • Outlook on performing Pragmatic Clinical Trials & Conclusions
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
11:45

ROCHE CURATED SESSION

round tables
12:05

Round Tables

Round Table A: AI for Drug Discovery - Investment Landscape
Dmitry Kaminskiy

Dmitry Kaminskiy, Managing Partner, Deep Knowledge Ventures

Round Table D: Analytics for Regulatory and Safety RWE and Epidemiology
Andrew Bate

Andrew Bate, Senior Director, Analytics Team Lead, Epidemiology, Pfizer

Round Table E: Digital Endopoints and Validation
Ieuan Clay

Ieuan Clay, Group Lead Digital Endpoints, Novartis

Round Table F: AI in Ageing Research and Longevity
Kristen Fortney

Kristen Fortney, Chief Executive Officer, Bioage Labs

Round Table G: Best practices and lessons learned on linked data zooming in on large scale data integration, data visualization and data curation
Filip Pattyn

Filip Pattyn, Scientific Lead, Ontoforce

Round Table I: Human Protein Atlas: Big data for human biology and precision medicine
Round Table J: Databiology
Round Table K: Digital Substudies- Big Data in Drug Discovery
Lena Granovsky

Lena Granovsky, Director, Analytics and Big Data, Teva Pharmaceuticals

Round Table L: Applied Health Science Research to Improve Clinical Outcomes
Daniel Zahnd

Daniel Zahnd, Head of Digital Health, Bern University of Applied Science

Round Table N: Empowering the Person in a Health System: Evidence for Effectiveness
Indra Joshi

Indra Joshi, Digital Health and AI Clinical Lead, NHS England

Round Table P: Wellcome Roundtable: Unlocking the Potential of Data to Improve Health for Everyone -What should Wellcome do about Data?
Chantal Wood

Chantal Wood, Programme Manager - Data for Science and Health, Wellcome Trust

Round Table Q: Using AI in Drug Development
Edward Painter

Edward Painter, Founder & CEI, A2A Pharmaceuticsls

Round Table R: Computing at the Exascale – Developing large scale genomics and heath record architecture
Jeremy Cohen

Jeremy Cohen, Senior Program Manager, Oak Ridge National Laboratory (ORNL)

Round Table T: Securing budget for organising data so its findable and usable
Martin Romacker

Martin Romacker, Data and Information Architect, Roche

Round Table V: Applications of RNA-seq data to drug discovery
Martin Akerman

Martin Akerman, CTO & Co-Founder, Envisagenics

Round Table X: Challenges in Data Curation and Quality
Ramin Daron

Ramin Daron, VP, Data Architecture and Technology, Takeda Pharmaceuticals

Round Table Y: Using prescriptive and predictive advanced analytics to mitigate risk and optimise increasingly complex clinical trials’
Liz Nevin

Liz Nevin, Senior IT Business Relationship Manager, Digital Therapeutics, AstraZeneca

Networking Lunch

AI, AUTOMATION AND MACHINE LEARNING

ANALYTICS PLATFORMS AND DATA SETS

NEXT GEN SEQUENCING

DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS

PRECISION MEDICINE

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:05

Chairs Opening Remarks

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:05

Chairs Opening Remarks

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
14:05

Chairs Opening Remarks

Mimi Choon-Quinones, Former Vice-Director, Clinical Operations EEMEA, Roche
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
14:05

Chairs Opening Remarks

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:10

Applied Technology and Innovation

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:10

Different whole genome sequencing strategies to study HPVs role in cancer development.

  • How HPV is involved in the development of different cancers
  • Strengths and weaknesses of different whole genome sequencing strategies to study HPV integrations in cancer
  • Time vs Money where should you invest?
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
14:10

Application of ML to lupus nephritis and extrarenal lupus clinical dataset - lesson learned and main takeaways

  • We adapted Eureqa software (Nutonian) to screen baseline and time-varying clinical and laboratory parameters for associations with outcome using pooled data from recent trials in lupus nephritis (LN) and extrarenal lupus (ERL)
  • In LN, Eureqa confirmed known associations with outcome but also several trivial associations. Eureqa did not identify meaningful associations between clinical variables and outcome in ERL trials
  • Eureqa is a potentially exciting tool to assist with discovery of novel associations in clinical data and hypothesis generation
Track 5- AI, AUTOMATION AND MACHINE LEARNING
14:30

Answering the Unasked Question – How AI Impacts Discoverability

With 2.5 million scientific papers published annually (and growing), researchers today are overwhelmed by published information. However, the mismatch between the amount of published information and the ability to consume it creates a serious discoverability problem that hampers knowledge-based enterprises. Standard AI techniques have been used to support call centers for years, and those same techniques can enable powerful federated search engines to volunteer results that have not been requested by the researcher. This is a powerful approach to address discoverability challenges can give organizations a competitive edge.Join CCC’s Álvaro Garcia Neto, Vice President of Engineering and Professional Services, to learn how AI and powerful federated search engines can improve discoverability for researchers and provide the right results – by answering unasked questions.
Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:30

How cloud-connected storage helps you simplify and accelerate large-scale data management in life sciences and medical imaging

Data management is complex, costly and time consuming. Your research teams need fast results, but storage silos and multiple management layers get in the way. Join this talk and learn how new cloud-enabled technologies merge seamlessly with big data technologies and search-based applications to overcome data access challenges. See how you can leverage a rich metadata repository, simplify data loading, and adopt ephemeral processing systems to accelerate information access across your organization.
Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:30

Using AI for drug target discovery

  • Case studies over the last five years
  • Precision Medicine based clinical trials
  • RWE in practice
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
14:30

PRECISION FOR MEDICINE

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
14:30

ROCHE TOPIC TBC

Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
14:50

Decision making platforms and data quality at pRED

Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
14:50

Omics and pathway analysis for disease understanding in pain

  • Pain as a disease
  • Interpretation of Omics data and Pathways
  • Pain Landscapes and Disease Understanding

AI, AUTOMATION AND MACHINE LEARNING

SOFTWARE & APPLICATIONS

EVIDENCE

DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS

PRECISION MEDICINE

Track 5- AI, AUTOMATION AND MACHINE LEARNING
15:40

Federated learning: leveraging the power of private data

  • Federated learning approach allows to build powerfull models from separated datasets
  • This techniques enables to build efficients models without compromising the privacy of individual datasets
  • Examples of applications in medicine
Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
15:40

RWE Presentation to be confirmed

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
15:40

The Genomics of Rare Diseases at Boston Children’s Hospital

  • The importance of phenotyping, transparency, and patient engagement
  • The delicate balance of data sharing, discovery, and translation to the clinic
  • Case studies of big data projects at a tertiary children’s hospital
  • Collaborations with Industry to make rare disease discoveries
Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
16:00

Data and AI to improve healthcare ecosystems

  • AI to improve the speed and quality of bi-directional learning between the patient and the drug discovery process
  • The role of big data in medicine to better diagnose and treat disease
  • How can data help unlock opportunities across Biopharma frontiers and Genomics research?
Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
16:00

Sponsor Available

Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
16:00

Sponsor Available

Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
16:00

Sponsor Available

Track 5- AI, AUTOMATION AND MACHINE LEARNING
16:20

From data lakes to actionable data

  • We can now build large collection of data spanning proprietary and public datasets (e.g.: -omics, RWE)
  • Leveraging these resources requires a data checking, cleansing and preparation process. This is an expensive process, that often needs to repeat for different investigations.
  • To which extent can we automate or semi-automate data curation processes?
  • We report on experiences and ideas in the use of rules, machine learning and AI systems to automate data curation process.
  • We discuss limitations, value and perspective developments.
Track 6- ANALYTICS PLATFORMS AND DATA SETS/ CLOUD PLATFORMS/ SOFTWARE & APPLICATIONS
16:20

How to Infuse the Human Perspective to Digital Health?"

  • Most paradigms of the digital health revolution, such as digital therapeutics, precision medicine, outcome-based health systems, and self-care are critically dependent on changing behavioural aspects of patients
  • Impactful digital health initiatives are therefore best co-developed with patients in a human-centric manner
  • Patients can participate in product and service development at scale through a novel service platform for patient engagement, specifically trained resources, and a network of relevant partners
Track 7- NEXT GEN SEQUENCING / REAL WORLD EVIDENCE
16:20

'Proof-of-Concept for using External Control Arms Derived from Electronic Health Records to Replace Control Arms from Randomized Controlled Trials

Thy Do, Head PHC Data Science RWD Oncology, Genentech
Track 8- DATA MANAGEMENT AND GENOMICS IN CLINICAL TRIALS
16:20

Towards fully-automated end-to-end AI-powered drug discovery

  • Cure a disease in a year challenge
Track 9- ROCHE CURATED SESSIONS/ PRECISION MEDICINE
16:20

Scaling up trustworthy data access for personalised care and research

  • Real World Evidence decision making and Precision Medicine need greater access to big health data: clinical data, genomic biomarkers, wellness and lifestyle.
  • Trustworthy data sharing is vital to scaling up data access: trust in privacy protection, trust in the quality of the data and trust in how data are used.
  • Stakeholders and efforts need to collaborate, especially with patients, to develop a portfolio of equitable and acceptable models that can be promoted globally.

End of Conference

last published: 09/Nov/18 16:45 GMT

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Alistair Wilmot
+44 (0)207 092 1174

alistair.wilmot@terrapinn.com


To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com